DLHC — Q3 FY2026 Financial Report Analysis

DLH Holdings' fiscal third quarter (April–June 2026) was the quarter its biggest legacy contract finished leaving. Revenue fell 46.9% to $44.2 million from $83.3 million, which the 10-Q attributes "primarily [to] the conversion of certain contracts in our contract portfolio to small business contractors across our customer base" — federal agencies moving work DLH used to lead into small-business set-asides, contracts reserved for smaller firms. The company swung to a $3.9 million operating loss, and a $10.4 million non-cash tax charge turned that into a net loss of $16.8 million, or $1.16 per share, against a $0.3 million profit a year earlier.

At a glance

• Revenue $44.2M, down 46.9%. Close to half the business disappeared in a year, mostly from contracts lost to small-business set-asides rather than from a funding freeze.
• VA pharmacy revenue $6.3M, down from $27.0M — and now gone. Both remaining Veterans Affairs mail-order pharmacy sites moved to new contractors during the quarter, so this work contributes nothing from the fourth quarter on.
• $128.7M of debt against $3.4M of quarterly adjusted EBITDA. Interest alone ($3.1M) used up almost all of the quarter's cash earnings before tax, depreciation and one-off costs, which leaves no margin for error.

The numbers

*Backlog figures compare June 30, 2026 with September 30, 2025 (fiscal year-end), the comparison the filing gives. Backlog is DLH's estimate of revenue left on signed contracts if every option is exercised; funded backlog is the part Congress has already appropriated and the agency has allocated.

For the first nine months of fiscal 2026, revenue was $172.4 million (down 34.5% from $263.3 million) and the net loss was $20.6 million, or $1.42 per share, versus net income of $2.3 million ($0.16) a year earlier.

Where the revenue went

DLH reports as a single segment, but it breaks out revenue by agency, and that breakdown shows every customer shrinking:

The VA decline is the cleanest story. All of DLH's VA revenue came from task orders at the Consolidated Mail Outpatient Pharmacy (CMOP) program. The VA re-solicited that work requiring a Service-Disabled Veteran-Owned Small Business as prime contractor, a category DLH doesn't qualify for. In the filing's words: "At the start of the third quarter, DLH performed services at two CMOP locations, both of which transitioned to new contractors during the quarter." The Defense and HHS declines are put down to the same set-aside conversions; the 10-Q doesn't name individual contracts.

HHS was 70.7% of third-quarter revenue (31.3 of 44.2), up from about 52% a year ago. That isn't growth at HHS; it's the other customers falling away faster.

Costs didn't fall as fast as revenue

Contract costs (the direct cost of delivering the work) fell $30.8 million, roughly in step with revenue, though they rose to 83.3% of revenue from 81.2%. The real squeeze was overhead. General and administrative costs fell only $0.3 million to $7.3 million, so as a share of revenue they nearly doubled, to 16.6% from 9.2%. Depreciation and amortization stayed at $4.0 million, mostly amortization of intangible assets from past acquisitions, which doesn't shrink when revenue does.

Management cut overhead during the quarter and booked $3.3 million of "cost scaling initiatives" (costs of resizing the company, $5.2 million year to date). Excluding those, "adjusted" operating income was still a loss of $0.6 million.

What the headline numbers hide

• The $16.8M net loss is mostly a non-cash tax write-off. DLH recorded a $10.4 million valuation allowance, which means it no longer expects to earn enough future profit to use its past tax losses and deductible interest, "based primarily on cumulative losses in recent periods". The deferred tax asset of $7.9 million at September 2025 is now zero. Excluding it, the net loss would have been about $6.4 million, or roughly $0.44 a share (our calculation). It's non-cash, but it's also management's own accounting judgment that profits are not around the corner.
• GAAP vs adjusted gap. Adjusted EBITDA of $3.4 million adds back $4.0 million of depreciation and amortization, $3.1 million of interest, the $9.8 million tax charge and the $3.3 million of restructuring costs. The restructuring add-back is reasonable if it doesn't recur, but this is already the second quarter of it ($5.2 million year to date).
• Cash flow is better than earnings, but partly because the company is shrinking. Operating cash flow was $4.2 million in the quarter and $3.2 million for nine months, against a $20.6 million nine-month net loss. A large part of that is working capital winding down: accounts receivable (money customers owe) fell to $24.4 million from $38.4 million at fiscal year-end as the old contracts were billed and collected. That cash comes once; it won't repeat as revenue stabilises.
• Debt is the central risk. Total debt is $128.7 million ($115.0 million term loan plus $13.7 million drawn on the revolving credit line), all at floating rates of about 7.8% since the interest-rate swap expired in January 2026. Cash was $0.2 million and unused revolver capacity just $5.0 million, down from $23.6 million because the line is limited by eligible receivables, which are shrinking. Required term-loan repayments rise to $23.75 million in fiscal 2027, and everything matures on December 8, 2027. On the third quarter's rate, debt is roughly 9-10 times annualized adjusted EBITDA (our rough calculation, not the covenant definition). The lenders amended the covenants on June 11, 2026, and DLH says it's in compliance, though the amendment allowed more add-backs to the EBITDA figure the leverage test uses (fiscal 2026 restructuring and lease-termination costs, and up to $3.0 million of profit from new contract awards).
• Goodwill is larger than equity. Goodwill is $138.2 million against shareholders' equity of $93.3 million. The falling share price triggered an impairment test this quarter. Management concluded fair value still exceeds book value, partly by applying a control premium to market value, so there was no write-down. Another weak quarter could change that.
• Leadership change. CEO Zach Parker retired at the end of the quarter; Kathryn JohnBull became President and CEO and Steve Oroho became CFO.
• Federal funding. The 10-Q says administration efficiency reviews "resulted in contract reductions, cancellations, and price renegotiations for the Company", but it doesn't expect broader funding disruptions to have a material impact. The revenue loss this quarter came from set-aside rules, not budget cuts.

Takeaway: The revenue cliff is now mostly behind DLH, since the VA pharmacy work is fully gone, but what's left is a company earning about $3.4 million a quarter in adjusted EBITDA while carrying $128.7 million of floating-rate debt due in December 2027. Whether it can grow fast enough to refinance that debt matters more than any single quarter's revenue.

Outlook

Management gave no numeric revenue or earnings guidance. In the July 29 earnings release, the new CEO said DLH expects "fourth-quarter revenue to be generated entirely by our technology-powered solutions" and that cost cuts should let it "maintain Adjusted EBITDA margins at approximately the same level as in the third quarter" (7.6%). Its stated priorities are organic growth, operating leverage and reducing debt "as rapidly as possible". Backlog of $408.5 million is down 20.6% since September, and funded backlog of $66.7 million covers less than two quarters at the current revenue rate.

Our read: with the roughly $6.3 million of third-quarter CMOP revenue gone, fourth-quarter revenue will probably be below the third quarter's $44.2 million unless new awards arrive quickly (our inference from the filing's figures, not company guidance). A 7.6% margin on a smaller base would leave adjusted EBITDA around $3 million a quarter, barely enough to cover interest of about $3 million. Prepayments mean scheduled term-loan payments are covered through December 2026 (and part of March 2027), which buys time, but the $23.75 million fiscal-2027 schedule and the December 2027 maturity still have to be met or refinanced. The things to watch in the fiscal 2026 10-K are new contract wins and whether backlog starts rising, whether receivables keep shrinking (which reduces both cash inflow and revolver headroom), any further covenant amendment, and the year-end goodwill test.